Effect of anti-macrophage inflammatory protein-1a on leukocyte trafficking and disease progression in experimental autoimmune uveoretinitis

Isabel Joan Crane, Heping Xu, Ayyakkannu Manivannan, Susan McKillop-Smith, Graeme Robert Lamont, Carol Ann Wallace, Janet Mary Liversidge, Peter Frederick Sharp, John Vincent Forrester

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)

Abstract

This study has enabled us to identify the influence of the chemokine, macrophage inflammatory protein-1alpha (MIP-1alpha), on leukocyte behavior at the blood-retina barrier in vivo and its link with the inflammatory process and disease pathogenesis. MIP-1alpha has not previously been thought to be effective under conditions of physiological shear flow. However, short-term anti-MIP-1alpha treatment inhibited leukocyte slowing and accumulation and subsequent extravasation of leukocytes at the blood-retina barrier in animals with experimental autoimmune uveoretinitis. This was effective predominantly in the post-capillary venules which have been shown to be the main site of passage of leukocytes across the blood-retina barrier. Long-term anti-MIP-1alpha treatment also prevented decreased leukocyte velocity and reduced disease severity as measured clinically, histologically and in terms of blood-retina barrier breakdown.

Original languageEnglish
Pages (from-to)402-410
Number of pages8
JournalEuropean Journal of Immunology
Volume33
Issue number2
DOIs
Publication statusPublished - Feb 2003

Keywords

  • macrophage inflammatory protein-1 alpha
  • CCL3
  • chemokine
  • cell trafficking
  • inflammation
  • ROLLING T-LYMPHOCYTES
  • ENDOTHELIAL-CELLS
  • FLOW CONDITIONS
  • CUTTING EDGE
  • CHEMOKINE
  • ENCEPHALOMYELITIS
  • UVEITIS
  • ARREST
  • MIP-1-ALPHA
  • EXPRESSION

Fingerprint

Dive into the research topics of 'Effect of anti-macrophage inflammatory protein-1a on leukocyte trafficking and disease progression in experimental autoimmune uveoretinitis'. Together they form a unique fingerprint.

Cite this